Abstracts Archive - Page 1887 of 2425 - ACR Meeting Abstracts

Abstract Number: 2490 • 2014 ACR/ARHP Annual Meeting
Assessment of Structural Benefits of SC Abatacept Using MRI in Patients with RA Who Have Failed 1 or 2 TNFs and Correlated with Clinical Outcomes As Measured By DAS28(ESR)
Norman B. Gaylis¹, Steven Needell² and Joanne Sagliani³, ¹Arthritis & Rheumatic Disease Specialties, Aventura, FL, ²Boca Radiology, Boca Raton, FL, ³Research, Arthritis & Rheumatic Disease Specialties, Aventura, FL
Background/Purpose: Previous studies1-2 suggest the structural benefit of IV abatacept in patients with RA who have previously failed MTX, TNF therapy or both. Objectives:This study…
Abstract Number: 2489 • 2014 ACR/ARHP Annual Meeting
Analysis of Early Neutropenia, Clinical Response, and Serious Infection Events in Patients Receiving Tofacitinib for Rheumatoid Arthritis
V. Strand¹, A. Dikranian², J. Beal³, K. Kwok³, S. Krishnaswami⁴, S. Wood⁴ and C. Nduaka⁴, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²San Diego Arthritis Medical Clinic, San Diego, CA, ³Pfizer Inc, New York, NY, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) decreases in mean peripheral neutrophil count were…
Abstract Number: 2488 • 2014 ACR/ARHP Annual Meeting
Relationship Between Different Clinical Measurements and Patient-Reported Outcomes
Roy Fleischmann¹, V Strand², B Wilkinson³, K Kwok⁴ and E Bananis³, ¹Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Department of Medicine, Dallas, TX, ²Biopharmaceutical Consultant, Portola Valley, CA, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we compare the relationship between clinical measures and patient-reported…
Abstract Number: 2487 • 2014 ACR/ARHP Annual Meeting
Effects of Tofacitinib on Health Care Resource Utilization and Work Productivity in US Patients with Rheumatoid Arthritis
V. Strand¹, R. Riese², R. Gerber², D. Gruben², A.G. Bushmakin², E.Y. Mahgoub³ and G. Wallenstein², ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we describe health care resource utilization (HCRU) and work…
Abstract Number: 2486 • 2014 ACR/ARHP Annual Meeting
Patient-Reported Outcomes Following 12 Months of Therapy with Abatacept (Plus Methotrexate or as Monotherapy) or Methotrexate and up to 6 Months after Treatment Withdrawal in Patients with Early Rheumatoid Arthritis
Daniel E. Furst¹, Vivian P. Bykerk², Gerd Burmester³, B Combe⁴, T W J Huizinga⁵, E Alemao⁶, D Wong⁶, C S Karyekar⁶ and P Emery⁷, ¹University of California at Los Angeles, Los Angeles, CA, ²Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ³Charité – University Medicine Berlin, Berlin, Germany, ⁴Monpellier University Hospital, Montpellier, France, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: Early biologic use can improve long-term control of RA,1,2 potentially leading to improved physical function and reduced pain. Recent EULAR recommendations support shared decisions…
Abstract Number: 2485 • 2014 ACR/ARHP Annual Meeting
Predictors of Drug-Free Remission Following Treatment with Abatacept (in Combination with Methotrexate or as Monotherapy) in Early Rheumatoid Arthritis
P Emery¹, Gerd Burmester², Vivian P. Bykerk³, B Combe⁴, Daniel E. Furst⁵, E Barre⁶, C S Karyekar⁷, D Wong⁷ and T W J Huizinga⁸, ¹University of Leeds, Leeds, United Kingdom, ²Charité – University Medicine Berlin, Berlin, Germany, ³Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁴Monpellier University Hospital, Montpellier, France, ⁵University of California at Los Angeles, Los Angeles, CA, ⁶Bristol-Myers Squibb, Braine-L’Alleud, Belgium, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the Phase IIIb, randomized, double-blind, active-controlled AVERT study, abatacept (ABA) + MTX and ABA monotherapy induced protocol-defined DAS remission (DAS28 [CRP]
Abstract Number: 2484 • 2014 ACR/ARHP Annual Meeting
Adding an Initial Six-Month Course of Infliximab to an Active Combination Treatment Is Cost Saving in Working-Aged Early Rheumatoid Arthritis Patients
Vappu Rantalaiho¹, Kari Puolakka², Janne Martikainen³, Hannu Kautiainen^4,5,6 and Marjatta Leirisalo-Repo^7,8, ¹Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland, ²Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland, ³Pharmacoeconomics and Outcomes Research Unit, School of Pharmacy, University of Eastern Finland, Kuopio, Finland, ⁴Department of General Practice, University of Helsinki, Helsinki, Finland, ⁵Unit of Primary Health Care, Turku University Hospital, Turku, Finland, ⁶Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland, ⁷Department of Clinical Medicine, University of Helsinki, Helsinki, Finland, ⁸Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland
Background/Purpose To study the cost-effectiveness of adding initial infliximab to a remission-targeted combination treatment with disease modifying antirheumatic drugs (DMARDs) in early rheumatoid arthritis (RA).…
Abstract Number: 2483 • 2014 ACR/ARHP Annual Meeting
Treatment Adjustment Strategy after Achieving Remission or Low Disease Activity in Rheumatoid Arthritis : A Systematic Review and Meta-Analysis
Sophie Henaux¹, Thomas Barnetche², Adeline Ruyssen Witrand³, Bruno Fautrel⁴, Alain G. Cantagrel⁵ and Arnaud Constantin⁶, ¹Centre de Rhumatologie, Hopital Purpan, Toulouse, France, ²Rheumatology, Bordeaux University Hospital, Bordeaux, France, ³Rheumatolgy, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁴GRC-UPMC 08; AP-HP, Rheumatology dépt, Pitié Salpêtrière Hospital, Paris, France, ⁵Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ⁶Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France
Conflict of interest : NONE.Background/Purpose Attaining remission or at least low-disease activity (LDA) is a goal achieved in a significant proportion of rheumatoid arthritis (RA) patients…
Abstract Number: 2482 • 2014 ACR/ARHP Annual Meeting
Use of Biologic Therapy As Monotherapy in Patients with Rheumatoid Arthritis
Antonio Gómez-Centeno¹, Olga Martínez², Francisco Javier Ballina³, José Manuel Rodríguez⁴, Jenaro Graña⁵, Manuel Brito⁶, Juana Sampedro⁷, Gerardo Iglesias⁸, Concepción Delgado⁹ and Indalecio Monteagudo¹⁰, ¹Hospital Parc Taulí, Sabadell, Spain, ²Hospital Virgen de la Concha, Zamora, Spain, ³Hospital Central de Asturias, Oviedo, Spain, ⁴Hospital Getafe, Getafe, Spain, ⁵Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Hospital Nuestra Señora Candelaria, Santa Cruz de Tenerife, Spain, ⁷Hospital Virgen de la Salud, Toledo, Spain, ⁸Complejo Hospitalario Palencia, Palencia, Spain, ⁹Hospital Clínico Lozano Blesa, Zaragoza, Spain, ¹⁰Hospital Gregorio Marañón, Madrid, Spain
Background/Purpose The treatment for Rheumatoid Arthritis (RA) is based on synthetic or biological disease-modifying drugs (DMARDs). Current guidelines recommend biologics in combination with methotrexate as…
Abstract Number: 2493 • 2014 ACR/ARHP Annual Meeting
Prediction of Remission and Low Disease Activity in DMARD-Refractory Patients with RA Treated with Golimumab
N Vastesaeger¹, P Durez², Bhaskar Dasgupta³, B Combe⁴, H Schulze-Koops⁵, I Louw⁶, J Wollenhaupt⁷, CAF Zerbini⁸, A Beaulieu⁹, K Pavelka¹⁰, M Lazaro¹¹, A Garcia Kutzbach¹², RJ Moots¹³, H Amital¹⁴, S Huyck¹⁵, B Fu¹⁵, M Govoni¹⁶ and HH Weng¹⁵, ¹MSD Belgium, Brussels, Belgium, ²Université Catholique de Louvain, Bruxelles, Belgium, ³Southend University Hospital, Essex, United Kingdom, ⁴Monpellier University Hospital, Montpellier, France, ⁵Division of Rheumatology, University of Munich, Munich, Germany, ⁶Panorama Medical Centre, Cape Town, South Africa, ⁷Schön Klinik Hamburg-Eilbek, Hamburg, Germany, ⁸Rheumatology, Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, ⁹Bureau 360, Centre de Rhumatologie, St-Louis, QC, Canada, ¹⁰Revmatologicky Ustav, Praha, Czech Republic, ¹¹IARI Instituto de Asistencia Reumatologica Integral, Buenos Aires, Argentina, ¹²AGAR Francisco Marroquin University, Guatemala City, Guatemala, ¹³University Hospital Aintree, Liverpool, United Kingdom, ¹⁴Medicine B, Sheba Medical Center, Tel-Hashomer, Israel, ¹⁵Merck & Co., Inc., Whitehouse Station, NJ, ¹⁶MSD Italy, Rome, Italy
Background/Purpose EULAR recommendations for RA therapy suggest addition of a biologic only if poor prognostic factors such as high disease activity are present. However, low…
Abstract Number: 2481 • 2014 ACR/ARHP Annual Meeting
Which Factors Influence the Prescription of Tocilizumab Alone or in Combination with DMARDsÂ in Rheumatoid Arthritis Patients in a Real Life Setting?: An Interim Analysis of Safety and Efficacy at 6 Months
Jacques Tebib¹, Isabelle Idier², Mathieu Coudert³, David Pau⁴, Rene-Marc Flipo⁵ and Jean-Francis Maillefert⁶, ¹Rheumatology, University Hospital Lyon, Lyon, France, ²Chugai Pharma, La Defense, France, ³Statistics, Experis IT, Nanterre, France, ⁴Statistics, Roche, Boulogne-Billancourt, France, ⁵Rheumatology, University Hospital Lille, Lille, France, ⁶Rheumatology, University Hospital Dijon, Dijon, France
Background/Purpose Baseline factors influencing the use of tocilizumab (TCZ) in monotherapy (Mono) instead of combination with DMARDs (Combo) in real-life practice in RA patients (pts)…
Abstract Number: 2479 • 2014 ACR/ARHP Annual Meeting
Utility of Adjustment of Administration Interval in Tocilizumab in Rheumatoid Arthritis
Shuntaro Saito, Keisuke Izumi, Yuko Kaneko, Katsuya Suzuki and Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose Interleukin-6 (IL-6) is considered a key cytokine in the pathogenesis of rheumatoid arthritis (RA). Tocilizumab (TCZ) is a monoclonal antibody which binds to membrane-bound…
Abstract Number: 2480 • 2014 ACR/ARHP Annual Meeting
Is there a Difference in the Effectiveness in the Treatment of Rheumatoid Arthritis with Rituximab when Using a Dose of 1 or 2 Grams per Cycle? a Systematic Review
Ana M. Ortiz¹, María Piedad Rosario², Carmen Martínez² and Isidoro González-Alvaro¹, ¹Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain
Background/Purpose: Since the description of the efficacy of rituximab (RTX) in treating patients with rheumatoid arthritis (RA), the use of this drug has been extended.…
Abstract Number: 2472 • 2014 ACR/ARHP Annual Meeting
The First, Multicenter, Double-Blind, Randomized, Parallel-Group Study of Certolizumab Pegol in Early Rheumatoid Arthritis Demonstrates Inhibition of Joint Damage Progression
Tatsuya Atsumi¹, Kazuhiko Yamamoto², Tsutomu Takeuchi³, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Yoshiya Tanaka⁶, Katsumi Eguchi⁷, Akira Watanabe⁸, Hideki Origasa⁹, Toshiharu Shoji¹⁰, Osamu Togo¹¹, Toshiyuki Okada¹², Désirée M. van der Heijde¹³, Nobuyuki Miyasaka¹⁴ and Takao Koike^15,16, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Kitakyushu, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of orthopedics, Nagoya University Graduate School and Faculty of Medicine, Nagoya, Japan, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁷Department of Rheumatology, Sasebo City General Hospital, Nagasaki, Japan, ⁸Division of Rheumatology, Department of Internal Medicine, School of Medicine, Tohoku University, Tokyo, Japan, ⁹Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Japan, ¹⁰Department of Clinical Research and Development, UCB Pharma, Tokyo, Japan, ¹¹Biometrics Group, UCB Pharma, Tokyo, Japan, ¹²Astellas Pharma Inc, Tokyo, Japan, ¹³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ¹⁴Department of Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁵NTT Sapporo Medical Center, Sapporo, Japan, ¹⁶Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose The efficacy and safety of certolizumab pegol (CZP)+methotrexate (MTX) therapy compared to MTX alone, in Japanese MTX-naïve early rheumatoid arthritis (RA) patients (pts) with…
Abstract Number: 2471 • 2014 ACR/ARHP Annual Meeting
Effect of Teriparatide in Patients with Osteoporosis and Rheumatoid Arthritis
Robin Dore¹, Kenneth G. Saag², Guillermo Valenzuela³, Kathleen Taylor⁴, Qiu He⁴, Jahangir Alam⁴ and Kelly D. Krohn⁵, ¹University of California, Los Angeles, CA, ²Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ³Integral Rheumatology and Immunology Specialists, Plantation, FL, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵DC 5208, Eli Lilly and Company, LLC, Indianapolis, Indiana, Indianapolis, IN
Background/Purpose: A common complication in rheumatoid arthritis (RA) is osteoporosis (OP) with increased incidence of fragility fractures. RA is the only disease specifically included…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].